Method and composition for the treatment of cancer
AssigneeDana-Farber Cancer Institute, Inc.
InventorsArthur B. Pardee, Chiang J. Li, Youzhi Li
Life of this patent
Estimating the term…
Abstract
We have surprisingly discovered that the administration of a G1 and/or S phase drug such as β-lapachone in combination with a G2/M drug such as a taxame derivative such as paclitaxel resulted in an unexpected greater than additive (i.e., synergistic) reduction in the number of tumors (and tumor volume) as compared with the administration of these agents alone. In addition, no signs of toxicity or weight loss were observed. The present invention relates to a method for treating a mammalian tumor using combinations such as a taxane derivative, preferably paclitaxel, and a β-lapachone, or a derivative or analog thereof.
Claims14
A method of treating a mammal having a solid tumor (or tumors) formed as a result of a cancer selected from the group consisting of melanoma, colon cancer, prostate cancer, lung cancer, pancreatic cancer, ovarian cancer and breast cancer, the method comprising:
- a) administering to the mammal an effective amount of a first compound comprising β-lapachone or derivatives thereof as the active ingredient;
- and
- b) administering to the mammal an effective amount of a G2/M phase drug.
A kit for the treatment of a mammalian tumor comprising separate vials containing β-lapachone or a derivative or analog thereof and a taxane derivative, with instructions for administering β-lapachone first.
A pharmaceutical composition comprising β-lapachone or a derivative or analog thereof and a taxane derivative and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.